Table 8Study characteristics and effect sizes of trials indicating greater sexual satisfaction with bupropion than escitalopram, fluoxetine, paroxetine, and sertraline

StudySample sizeComparisonEffect measureP valueComments
Higher rates of sexual satisfaction with bupropion
Clayton et al., 200642830EscitalopramIncidence of worsened sexual functioning was significantly lower in patients on bupropion XL than on escitalopramP<0.05DSM-IV criteria for sexual dysfunction disorders

No statistically significant differences in efficacy outcome measures at endpoint (week 8)
Coleman et al., 2001110456Fluoxetine,

Placebo
Significantly more bupropion SR patients were satisfied with overall sexual functioning (analysis only for patients satisfied at baseline; no rates reported)P<0.05DSM-IV criteria for sexual dysfunction disorders

No statistically significant differences in efficacy outcome measures at endpoint (week 8)
Coleman et al., 1999115364SertralineBeginning at day 21 significantly more patients on bupropion SR were satisfied with their sexual functioning (endpoint: 85% compared with 62%)

Endpoint:
RRR: 0.59
RD: 0.22
NNT: 5
P<0.05DSM-IV criteria for sexual dysfunction disorders

No statistically significant differences in efficacy outcome measures at endpoint (week 8)
Croft et al., 1999114360Sertraline

Placebo
Beginning at day 7 through day 42 significantly more bupropion SR patients were satisfied with overall sexual functioning; difference was not statistically significant at endpoint (75% compared with 65%)

endpoint:
RRR: 0.29
RD: 0.10
NNT: 10
P<0.05Assessment of sexual function in an investigator- conducted structured interview

No statistically significant differences in efficacy outcome measures at endpoint (week 8)
Feighner et al. 199110961FluoxetineNRNRBupropion IR; study does not report on differences in sexual adverse events
Kavoussi et al. 1997113, 128248Sertraline,Significantly more patients on sertraline experienced orgasm delays and/or failure

Women: 41% compared with 7%
RRR: 0.85
RD: 0.38
NNT: 3

Men: 61% compared with 10%
RRR: 0.84
RD: 0.51
NNT: 2
P<0.01Assessment of sexual function in an investigator- conducted structured interview;

No statistically significant differences in efficacy outcome measures at endpoint (week 16)
Higher overall satisfaction with sexual functioning with bupropion SR at endpoint (79% compared with 58%)

RRR: 0.50
RD: 0.21
NNT: 5
P<0.001

Abbreviations: RRR, Relative Risk Reduction; RD, Risk Difference; NNT, Number Needed to Treat

From: Results

Cover of Drug Class Review: Second-Generation Antidepressants
Drug Class Review: Second-Generation Antidepressants: Final Update 5 Report [Internet].
Gartlehner G, Hansen RA, Reichenpfader U, et al.
Portland (OR): Oregon Health & Science University; 2011 Mar.
Copyright © 2011 Oregon Health & Science University.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.